GPC1 and neoplasm: Anti-GPC1 monoclonal antibodies have been utilized to develop an antibody-drug-conjugate (ADC), immunotoxin, bispecific T-cell engager (BiTE), and CAR T cells against GPC1-positive tumor cells and their antitumor efficacy has been demonstrated in preclinical models15–20.